

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 September 2020 (24.09.2020)



(10) International Publication Number
WO 2020/187998 A1

(51) International Patent Classification:

A61K 38/00 (2006.01) *C07K 14/82* (2006.01)
A61K 39/00 (2006.01) *C07K 16/28* (2006.01)
A61K 39/395 (2006.01) *A61P 35/00* (2006.01)
A61K 45/06 (2006.01)

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2020/057492

(22) International Filing Date:

18 March 2020 (18.03.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

19382194.9 19 March 2019 (19.03.2019) EP

(71) Applicants: **FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÒGICA DE VALL HEBRON** [ES/ES]; Natzaret, 115, E-08025 Barcelona (ES). **INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS** [ES/ES]; Passeig Lluís Companys, 23, E-08010 Barcelona (ES). **PEPTOMYC, S.L.** [ES/ES]; Natzaret, 115-117, E-08035 Barcelona (ES).

(72) Inventors: **SOUCEK, Laura**; FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÒGICA DE VALL HEBRON, Natzaret, 115, E-08025 Barcelona (ES). **BEAULIEU, Marie-Eve**; PEPTOMYC, S.L., Natzaret, 115-117, E-08035 Barcelona (ES). **CASACUBERTA-SERRA, Sílvia**; Sardenya, 337, 5e, 4ra, E-08025 Barcelona (ES).

(74) Agent: **ABG INTELLECTUAL PROPERTY LAW, S.L.**; Avda. de Burgos, 16D, Edificio EUROMOR, E-28036 Madrid (ES).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))



WO 2020/187998 A1

(54) Title: COMBINATION THERAPY WITH OMOMYC AND AN ANTIBODY BINDING PD-1 OR CTLA-4 FOR THE TREATMENT OF CANCER

(57) Abstract: The invention relates to a combination of an immuno-oncology agent with Omomyc, a functionally equivalent variant thereof, a conjugate comprising Omomyc or said functionally equivalent variant, a polynucleotide encoding said polypeptides, a vector comprising said polynucleotide and a cell capable of secreting the polypeptide or the conjugate. The invention also relates to pharmaceutical compositions containing the combination of the invention and to their medical uses, particularly their uses in the treatment of cancer.